PureTech Health (PTCHF) FDA Approvals $1.65 0.00 (0.00%) As of 11/13/2026 Add Compare Share Share FDA Events Stock AnalysisChartFDA EventsFinancialsSEC Filings PureTech Health's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by PureTech Health (PTCHF). Over the past two years, PureTech Health has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as SPT-320. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. SPT-320 FDA Regulatory Events SPT-320 is a drug developed by PureTech Health for the following indication: to treat generalized anxiety disorder. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Presentation - October 9,2026Presentation Drug: SPT-320Announced Date: October 9, 2026Indication: to treat generalized anxiety disorderOther Companies Involved: NASDAQ:PRTC AnnouncementSeaport Therapeutics, Inc announced the presentation of Phase 1 clinical data for GlyphAgo™ (SPT-320 or Glyph Agomelatine) at the 39th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 10-13, 2026, in Munich, Germany.AI SummarySeaport Therapeutics announced that it will present Phase 1 results for GlyphAgo (SPT-320), its oral agomelatine prodrug, at the 39th European College of Neuropsychopharmacology Congress in Munich, October 10–13, 2026. The presentation is the first detailed scientific report from the program and includes results from a trial involving 174 healthy volunteers. Results showed that GlyphAgo increased agomelatine bioavailability 6.8-fold and reduced pharmacokinetic variability by about 10 times compared with unmodified agomelatine. Drug exposure rose with dose, was not affected by food, and did not build up over seven days of dosing. The company says therapeutically relevant drug levels were reached at lower doses designed to reduce liver exposure and may lower the risk of liver enzyme elevations. These findings support further study but do not yet establish clinical benefit or reduced liver risk. Seaport has begun a Phase 2a trial in adults with generalized anxiety disorder and sleep disturbance, with results expected in early 2028. A larger Phase 2/3 trial is planned for 2027.Read AnnouncementDose Update - October 7,2026Dose Update Phase 2aDrug: SPT-320Announced Date: October 7, 2026Indication: to treat generalized anxiety disorderOther Companies Involved: NASDAQ:PRTC AnnouncementSeaport Therapeutics, Inc announced that the first patient has been dosed in a Phase 2a clinical trial in Australia evaluating GlyphAgoTM (SPT-320 or Glyph Agomelatine), in adults with generalized anxiety disorder ("GAD") and sleep disturbance. GlyphAgo is a novel, "Glyphed" oral prodrug of agomelatine, a clinically validated MT1/MT2 melatonin receptor agonist and serotonin 2C (5-HT2C) receptor antagonist.AI SummarySeaport Therapeutics has dosed the first patient in an Australian Phase 2a trial of GlyphAgo (SPT-320), an oral prodrug of agomelatine, in adults with generalized anxiety disorder (GAD) and sleep disturbance. GlyphAgo is designed to improve absorption through the intestinal lymphatic system, bypassing first-pass liver metabolism. Its active drug, agomelatine, acts on melatonin and serotonin receptors. The six-week study will compare two GlyphAgo doses. Researchers will assess sleep using patient reports and brain-wave measures, and track anxiety symptoms, overall illness severity, safety, tolerability, and drug levels. The trial aims to show whether the medicine has effects on sleep and anxiety in this patient group. In a Phase 1 study, GlyphAgo showed 6.8 times the bioavailability of unmodified agomelatine. The tested doses achieved relevant drug exposure and were well tolerated, with no reported liver-related adverse events. These findings support the trial’s dose choices, but do not establish clinical benefit or reduced liver risk. Seaport expects topline Phase 2a results in early 2028.Read Announcement PureTech Health FDA Events - Frequently Asked Questions Has PureTech Health received FDA approval? As of now, PureTech Health (PTCHF) has not received any FDA approvals for its therapy in the last two years. What drugs has PureTech Health submitted to the FDA? In the past two years, PureTech Health (PTCHF) has reported FDA regulatory activity for SPT-320. What is the most recent FDA event for PureTech Health? The most recent FDA-related event for PureTech Health occurred on October 9, 2026, involving SPT-320. The update was categorized as "Presentation," with the company reporting: "Seaport Therapeutics, Inc announced the presentation of Phase 1 clinical data for GlyphAgo™ (SPT-320 or Glyph Agomelatine) at the 39th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 10-13, 2026, in Munich, Germany." What conditions do PureTech Health's current drugs treat? Currently, PureTech Health has one therapy (SPT-320) targeting the following condition: to treat generalized anxiety disorder. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events ACADIA Pharmaceuticals FDA EventsEikon Therapeutics FDA EventsIonis Pharmaceuticals FDA EventsKaryopharm Therapeutics FDA EventsPulmonx FDA EventsMetaVia FDA EventsNeonc Technologies FDA EventsRegeneron Pharmaceuticals FDA EventsSELLAS Life Sciences Group FDA EventsSanofi FDA EventsVeru FDA EventsMedtronic FDA EventsAclaris Therapeutics FDA EventsBioVie FDA EventsBioLineRx FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies AstraZeneca FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for OTCMKTS:PTCHF last updated on 10/9/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PureTech Health plc Please log in to your account or sign up in order to add this asset to your watchlist. Share PureTech Health With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Presentation - October 9,2026Presentation Drug: SPT-320Announced Date: October 9, 2026Indication: to treat generalized anxiety disorderOther Companies Involved: NASDAQ:PRTC AnnouncementSeaport Therapeutics, Inc announced the presentation of Phase 1 clinical data for GlyphAgo™ (SPT-320 or Glyph Agomelatine) at the 39th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 10-13, 2026, in Munich, Germany.AI SummarySeaport Therapeutics announced that it will present Phase 1 results for GlyphAgo (SPT-320), its oral agomelatine prodrug, at the 39th European College of Neuropsychopharmacology Congress in Munich, October 10–13, 2026. The presentation is the first detailed scientific report from the program and includes results from a trial involving 174 healthy volunteers. Results showed that GlyphAgo increased agomelatine bioavailability 6.8-fold and reduced pharmacokinetic variability by about 10 times compared with unmodified agomelatine. Drug exposure rose with dose, was not affected by food, and did not build up over seven days of dosing. The company says therapeutically relevant drug levels were reached at lower doses designed to reduce liver exposure and may lower the risk of liver enzyme elevations. These findings support further study but do not yet establish clinical benefit or reduced liver risk. Seaport has begun a Phase 2a trial in adults with generalized anxiety disorder and sleep disturbance, with results expected in early 2028. A larger Phase 2/3 trial is planned for 2027.Read Announcement
Dose Update - October 7,2026Dose Update Phase 2aDrug: SPT-320Announced Date: October 7, 2026Indication: to treat generalized anxiety disorderOther Companies Involved: NASDAQ:PRTC AnnouncementSeaport Therapeutics, Inc announced that the first patient has been dosed in a Phase 2a clinical trial in Australia evaluating GlyphAgoTM (SPT-320 or Glyph Agomelatine), in adults with generalized anxiety disorder ("GAD") and sleep disturbance. GlyphAgo is a novel, "Glyphed" oral prodrug of agomelatine, a clinically validated MT1/MT2 melatonin receptor agonist and serotonin 2C (5-HT2C) receptor antagonist.AI SummarySeaport Therapeutics has dosed the first patient in an Australian Phase 2a trial of GlyphAgo (SPT-320), an oral prodrug of agomelatine, in adults with generalized anxiety disorder (GAD) and sleep disturbance. GlyphAgo is designed to improve absorption through the intestinal lymphatic system, bypassing first-pass liver metabolism. Its active drug, agomelatine, acts on melatonin and serotonin receptors. The six-week study will compare two GlyphAgo doses. Researchers will assess sleep using patient reports and brain-wave measures, and track anxiety symptoms, overall illness severity, safety, tolerability, and drug levels. The trial aims to show whether the medicine has effects on sleep and anxiety in this patient group. In a Phase 1 study, GlyphAgo showed 6.8 times the bioavailability of unmodified agomelatine. The tested doses achieved relevant drug exposure and were well tolerated, with no reported liver-related adverse events. These findings support the trial’s dose choices, but do not establish clinical benefit or reduced liver risk. Seaport expects topline Phase 2a results in early 2028.Read Announcement